| editorial | Q871232 |
| scholarly article | Q13442814 |
| P2093 | author name string | Marc Blockman | |
| P2860 | cites work | Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation | Q22305336 |
| Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks | Q24244298 | ||
| Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines | Q24632951 | ||
| Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients | Q28169189 | ||
| Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial | Q34134664 | ||
| Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines | Q34252907 | ||
| Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial | Q34633608 | ||
| Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). | Q34788530 | ||
| Warfarin for non-rheumatic atrial fibrillation: five year experience in a district general hospital | Q35583062 | ||
| Mortality from adverse drug reactions in adult medical inpatients at four hospitals in South Africa: a cross-sectional survey | Q36125525 | ||
| Effect of study setting on anticoagulation control: a systematic review and metaregression | Q36473615 | ||
| Adverse Drug Reactions Causing Admission to Medical Wards: A Cross-Sectional Survey at 4 Hospitals in South Africa | Q36993353 | ||
| Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review | Q37661890 | ||
| Vitamin K antagonists and time in the therapeutic range: implications, challenges, and strategies for improvement | Q38086125 | ||
| Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centers and countries: an analysis of patients receiving warfarin in the randomized evaluation of long-term anticoagulati | Q38463419 | ||
| Novel CYP2C9 and VKORC1 gene variants associated with warfarin dosage variability in the South African black population | Q42733103 | ||
| People aged over 75 in atrial fibrillation on warfarin: the rate of major hemorrhage and stroke in more than 500 patient-years of follow-up | Q45196981 | ||
| Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States | Q46071735 | ||
| Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range | Q46173062 | ||
| P433 | issue | 6 | |
| P921 | main subject | (RS)-warfarin | Q407431 |
| P304 | page(s) | 344-345 | |
| P577 | publication date | 2017-11-01 | |
| P1433 | published in | Cardiovascular Journal of Africa | Q26830987 |
| P1476 | title | Warfarin: better the devil you know | |
| P478 | volume | 28 |
Search more.